L

Lineage Cell Therapeutics Inc
F:BT3

Watchlist Manager
Lineage Cell Therapeutics Inc
F:BT3
Watchlist
Price: 1.41 EUR 1.44% Market Closed
Market Cap: 266.1m EUR

Net Margin

-118.7%
Current
Declining
by 50.1%
vs 3-y average of -68.6%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-118.7%
=
Net Income
$-40.9m
/
Revenue
$10.9m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-118.7%
=
Net Income
€-40.9m
/
Revenue
$10.9m

Peer Comparison

Country Company Market Cap Net
Margin
US
Lineage Cell Therapeutics Inc
TASE:LCTX
427m ILS
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
372.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
175.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
153.8B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
76.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.6B AUD
Loading...
NL
argenx SE
XBRU:ARGX
40.8B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD
Loading...
No Stocks Found

Market Distribution

Lower than 86% of companies in the United States of America
Percentile
14th
Based on 15 072 companies
14th percentile
-118.7%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Lineage Cell Therapeutics Inc
Glance View

Market Cap
266.1m EUR
Industry
Biotechnology

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 57 full-time employees. The firm is engaged in developing cell therapies for unmet medical needs. The company is focused on developing therapies for degenerative retinal diseases, neurological conditions associated with demyelination and aiding the body in detecting and combating cancer. Specifically, it is testing therapies to treat dry age-related macular degeneration, spinal cord injuries and non-small cell lung cancer. The firm has three allogeneic cell therapy programs: OpRegen, OPC1 and VAC2. OpRegen is a retinal pigment epithelium cell replacement therapy being developed for the treatment of advanced dry age-related macular degeneration (AMD) with geographic atrophy. OPC1 is an oligodendrocyte progenitor cell therapy that is being developed for acute spinal cord injuries (SCI). VAC2 is an allogeneic cancer immunotherapy of antigen-presenting dendritic cells that is being developed for non-small cell lung cancer.

BT3 Intrinsic Value
1.28 EUR
Overvaluation 9%
Intrinsic Value
Price
L
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-118.7%
=
Net Income
$-40.9m
/
Revenue
$10.9m
What is Lineage Cell Therapeutics Inc's current Net Margin?

The current Net Margin for Lineage Cell Therapeutics Inc is -118.7%, which is below its 3-year median of -68.6%.

How has Net Margin changed over time?

Over the last 3 years, Lineage Cell Therapeutics Inc’s Net Margin has decreased from -109.5% to -118.7%. During this period, it reached a low of -111.2% on Jul 30, 2025 and a high of -45.5% on Mar 31, 2025.

Back to Top